Methods comprising a biocidal polyamine

Patent metadata

Field	Value
Publication number	US-10440955-B2
Application number	US-201715806701-A
Country	US
Kind code	B2
Filing date	Nov 8, 2017
Priority date	May 22, 2013
Publication date	Oct 15, 2019
Grant date	Oct 15, 2019

Abstract

Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.

First claim

What is claimed is:

1. A method for dispersing or killing a biofilm on a subject, the method comprising a step of topically, orally, transmucosally, vaginally, or rectally administering an anti-biofilm composition to a surface of the subject, thereby effectively dispersing or killing the biofilm;
wherein the anti-biofilm composition comprises
(i) a pharmaceutically acceptable carrier; and
(ii) a therapeutically effective amount of a biocidal polyamine compound;
wherein the biocidal polyamine compound is selected from the group consisting of:

and a salt thereof;
wherein:
each R a is independently a group of Formula II:

each of the A n members is independently selected from the group consisting of CR a and CR 5 ; or, alternatively, a pair of adjacent A n members join to form a cycloalkyl, aryl, heterocyclyl, or heterocycloaryl ring; wherein at least one A n member and at most three A n members are independently selected CR a ,
each R 1a and R 1b is a member independently selected from the group consisting of hydrogen, fluoro, alkyl, and fluoroalkyl;
each R 2a , R 2b , R 2c , and R 2d is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; alternatively, a pair of R 2n members from the R a group independently selected from the group R 2a and R 2b , and R 2c and R 2d join to form a ring independently selected from the group consisting of spirocycloalkyl and spiroheterocycyl; or, alternatively, the R 2a and the R 2c from the R a group join to form a ring independently selected from the group consisting of cycloalkyl and heterocycyl;
each R m is a member independently selected from the group consisting of —CR 2a R 2b —, —CR 2c R 2d —, —C(R 2a )=(R 2b )—, —CC— and —C(R 2a )(R 2b )-L 2 -C(R 2c )(R 2d )—;
m is 1;
each L 1 and L 2 is a member independently selected from the group consisting of a bond, —O—, —C(O)O—, —NR 4 —, —NR 4 C(O)—, and C(O)NR 4 —;
each R 3 is a member independently selected from the group consisting of —Z 1 —Y 1 —R 4 and —Z 1 —Y 1 —Y 2 —R 4 ;
each R 4 is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or, alternatively, for a —N(R 4 ) 2 group, one of the two R 4 in the group is a member selected from the group consisting of —(CO)OR 6a —, (CO)N(R 6a )(R 6b ), and —C(NR 6a )N(R 6b )(R 6c );
each R 5 is a member independently selected from the group consisting of hydrogen, alkyl, hydroxyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, aryloxy, arylamino, cycloalkyl, cycloalkoxy, cycloalkylamino, heterocyclyl, heterocycyloxy, heterocycylamino, halo, haloalkyl, fluoroalkyloxy, heteroaryl, heteroaryloxy, heteroarylamino, arylalkyl, arylalkyloxy, arylalkylamino, heteroarylalkyl, heteroarylalkyloxy, heteroarylalkylamino; hydroxyalkyl, aminoalkyl, and alkylaminoalkyl;
each Y 1 and Y 2 is an independently selected group of Formula IA:

each Z 1 and Z 2 is an independently selected NR 4 ; and
each R 6a , R 6b , and R 6c is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, cycloalkyl, and heteroarylalkyl; or, alternatively, two R 6n members R 6a and R 6b or R 6a and R 6c form a heterocycyl ring;
wherein the biocidal polyamine compound comprises at least two primary or secondary amino groups.

2. The method of claim 1 , wherein:
each R 2a , R 2b , R 2c , and R 2d is a member independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl.

3. The method of claim 2 , wherein:
each R 1a and R 1b is a member independently selected from the group consisting of hydrogen and alkyl.

4. The method of claim 1 , wherein the biocidal polyamine compound comprises at least four primary or secondary amino groups.

5. The method of claim 1 , wherein the biocidal polyamine compound is selected from the group consisting of

and a salt thereof;
wherein each A n member is an independently selected CR 5 .

6. The method of claim 5 , wherein the biocidal polyamine compound is selected from the group consisting of

and a salt thereof; and
wherein R a is an independently selected group of Formula VII:

7. The method of claim 5 , wherein R a is —CH 2 [NH(CH 2 ) n ] p NH 2 ;
wherein each n is an integer independently selected from 3 to 12; and
wherein each p is an integer independently selected from 1 to 3.

8. The method of claim 5 , wherein the biocidal polyamine compound is selected from the group consisting of

and a salt thereof.

9. The method of claim 1 , wherein the anti-biofilm composition is a liquid, a gel, a paste, or a powder.

10. The method of claim 1 , wherein the biofilm comprises an antibiotic-resistant bacterial species.

11. The method of claim 1 , wherein the anti-biofilm composition is an aerosol spray, a solution, a suspension, a gel, a paste, a cream, or a foam.

12. The method of claim 11 , wherein the anti-biofilm composition is the cream.

13. The method of claim 1 , wherein the anti-biofilm composition is a tablet, a pill, a troche, or a capsule.

14. The method of claim 1 , the surface is a dermal surface, a mucosal surface, an oral surface, a urinary tract surface, a vaginal tract surface, or a lung surface.

15. The method of claim 1 , wherein the surface is skin or soft tissue that has been compromised by dermatitis, ulcers, a burn injury, or trauma.

16. The method of claim 1 , wherein the method comprises a step of treating a patient with a biofilm-related disorder.

17. The method of claim 16 , wherein the biofilm-related disorder is an infection, pneumonia, cystic fibrosis, otitis media, a urinary tract disorder, a periodontal disease, bronchiectasis, dental caries, or acne.

Assignees

• Curza Global Llc
• Univ Utah Res Found

Inventors

• Looper Ryan
• Williams Dustin
• Jeyapalina Sujeevini
• Haussener Travis
• Sebahar Paul R
• Reddy Hariprasada R Kanna

Classifications

• A61L2103/15

  Laboratory, medical or dentistry appliances, e.g. catheters or sharps · CPC title

• A61L2103/05

  Living organisms or biological materials · CPC title

• C07D317/58

  Radicals substituted by nitrogen atoms (nitro radicals C07D317/52) · CPC title

• C07D295/135

  with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings · CPC title

• A61L2/235

  cellular, porous or foamed · CPC title